RSHZ19 monoclonal antibody

a respiratory syncytial virus (RSV)-specific reshaped human monoclonal antibody (IgG1 framework) used for treatment or prophylaxis of human RSV infection

Also Known As:

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Respiratory Tract Diseases (Respiratory Tract Disease) 05/01/1999 - "The doses of SB 209763 studied may have been insufficient to confer protection against RSV lower respiratory tract disease; these results suggest that additional trials using higher doses of monoclonal antibody for immunoprophylaxis should be considered."
2.	Premature Birth (Birth, Premature) 05/01/1999 - "No other factor (dose, weight, gender, race, premature birth, or bronchopulmonary dysplasia) was observed to alter the population pharmacokinetics of SB 209763 in this study of infants and young children. "
3.	Bronchopulmonary Dysplasia 05/01/1999 - "Forty-three infants who were either delivered prematurely (</=35 weeks' gestation) or exhibited bronchopulmonary dysplasia were administered either single or repeat (two doses, 8 weeks apart) intramuscular injections of SB 209763 at a concentration of 0.25, 1.25, 5.0, or 10.0 mg/kg or of a placebo. " 05/01/1999 - "No other factor (dose, weight, gender, race, premature birth, or bronchopulmonary dysplasia) was observed to alter the population pharmacokinetics of SB 209763 in this study of infants and young children. "
4.	Body Weight (Weight, Body) 05/01/1999 - "At least 57% of subjects dosed at 1.25 to 10.0 mg of SB 209763 per kg of body weight who were seronegative at baseline experienced a fourfold or greater increase in fusion inhibition titer. "

Related Drugs and Biologics

1.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Intramuscular Injections